Abstract
Objectives: Aspirin (ASA) is commonly used in CVD prevention because irreversibly inhibits platelet cyclooxygenase-1 (COX-1) and thromboxane-mediated platelet aggregation. However, some subjects fail to benefit from ASA treatment. Among the mechanisms to explain ASA failure, oxidative stress has emerged as a relevant factor. We investigated the association of oxidative stress (urinary 8-isoPGF2α) in a cohort of CAD patients on ASA treatment categorized by tertiles of urinary 11-dehydro thromboxane B2 (11dhTxB2) response.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
